LMNL(Delisted)
Liminal BioSciencesยทNASDAQ
--
--(--)
LMNL Profile
Liminal Biosciences Inc.
A clinical stage biopharmaceutical company focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases
440 Armand-Frappier Boulevard, Suite 300, Laval, Quebec, H7V 4B4
--
Liminal BioSciences Inc. was incorporated on October 14, 1994 under the Canadian Business Companies Act. The company is a developmental biopharmaceutical company focused on discovering and developing new and unique small molecule therapies that regulate the G protein-coupled receptor, or GPCR pathway. The company is designing proprietary novel small molecule therapeutic candidates with the goal of developing best/first-in-class therapies for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using a comprehensive drug discovery platform, medicinal chemistry expertise and deep understanding of GPCR biology.
